Global Epilepsy Drugs Market 2018-2022| Rise in Epilepsy Incidence to Drive Growth | Technavio

Technavio analysts forecast the global epilepsy drugs market to grow at a CAGR of over 7% by 2022. (Graphic: Business Wire)

LONDON--()--Technavio analysts forecast the global epilepsy drugs market to grow at a CAGR of over 7% during the forecast period, according to their latest market research report.

The increase in epilepsy management costs is one of the major trends being witnessed in the global epilepsy drugs market 2018-2022. Direct costs associated with epilepsy are costs of hospitalization, outpatient treatment, anticonvulsants, diagnostic workup, rehabilitation, ancillary treatment, transportation, special equipment, nursing care, and parents’ co-payments. Indirect costs include the reduction of working hours, quitting work, and days off due to seizures. Epilepsy treatment is associated with high directs costs due to frequent inpatient admissions and high indirect costs due to productivity losses.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

According to Technavio analysts, one of the key factors contributing to the growth of the global epilepsy drugs market is the rise in epilepsy incidence:

Global epilepsy drugs market: Rise in epilepsy incidence

The high variation in the prevalence and incidence of epilepsy globally can be attributed to the factors such as the difference in access to healthcare, regional environment exposures such as neurocysticercosis, and socioeconomic status in different countries.

According to a senior analyst at Technavio for research on the central nervous system, “The incidence rate of epilepsy changes with both age and sex. Many studies in the epileptic population have shown a general trend towards an increase in prevalence in adolescence and early adulthood. Due to the high incidence of epilepsy, several programs have been initiated globally to develop effective and safe drugs for the treatment of seizures in epileptic patients.”

Global epilepsy drugs market: Segmentation analysis

The global epilepsy drugs market research report provides market segmentation by drug activity spectrum (narrow spectrum drugs and broad-spectrum drugs) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

The Americas held the largest share of the market in 2017, accounting for close to 63% share, followed by EMEA and APAC respectively. The region dominates the market owing to the increase in epilepsy treatment due to the high incidence and prevalence of the disorder and advanced treatment options.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio analysts forecast the global epilepsy drugs market to grow at a CAGR of over 7% by 2022.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com